Literature DB >> 32292542

Selective Estrogen Receptor Degraders for the Potential Treatment of Cancer.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2020        PMID： 32292542      PMCID： PMC7153008          DOI： 10.1021/acsmedchemlett.0c00107

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  3 in total

Review 1.  Comparison of the roles of estrogens and androgens in breast cancer and prostate cancer.

Authors:  Wen-Jing Liu; Gang Zhao; Chen-Yan Zhang; Chang-Qing Yang; Xiang-Bin Zeng; Jin Li; Kun Zhu; Shi-Qi Zhao; Hui-Meng Lu; Da-Chuan Yin; Sheng-Xiang Lin
Journal:  J Cell Biochem       Date:  2019-11-06       Impact factor: 4.429

Review 2.  ERα-targeted endocrine therapy, resistance and the role of GPER.

Authors:  Richard A Pepermans; Eric R Prossnitz
Journal:  Steroids       Date:  2019-09-10       Impact factor: 2.668

Review 3.  Current shreds of evidence on the anticancer role of EGCG in triple negative breast cancer: an update of the current state of knowledge.

Authors:  Sabrina Bimonte; Marco Cascella; Antonio Barbieri; Claudio Arra; Arturo Cuomo
Journal:  Infect Agent Cancer       Date:  2020-01-10       Impact factor: 2.965
  3 in total
  1 in total

1.  Dual antagonists of α5β1/αvβ1 integrin for airway hyperresponsiveness.

Authors:  Aparna Sundaram; Chun Chen; Nilgun Isik Reed; Sean Liu; Seul Ki Yeon; Joel McIntosh; You-Zhi Tang; Hyunjun Yang; Marc Adler; Richard Beresis; Ian B Seiple; Dean Sheppard; William F DeGrado; Hyunil Jo
Journal:  Bioorg Med Chem Lett       Date:  2020-09-29       Impact factor: 2.823
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.